| Document |
Document Title |
|
WO/2021/206488A1 |
The present invention relates to an anthracene compound represented by [Formula A] and an organic light-emitting element comprising same, wherein [Formula A] is as described in the detailed description of the invention.
|
|
WO/2021/197344A1 |
Disclosed are a salt type and a crystal form (I) of a diazaspiropyran compound, and a preparation method therefor. Also disclosed is the use of the salt type and the crystal form in the preparation of drugs for treating related diseases.
|
|
WO/2021/186324A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharm...
|
|
WO/2021/174351A1 |
Particular antimicrobials are identified for efficacy in a composition with DispersinB to enhance biofilm dispersal and inactivation of biofilm embedded bacteria.
|
|
WO/2021/170913A1 |
Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic o...
|
|
WO/2021/166552A1 |
Provided is an organic electroluminescence element including a positive electrode, a light-emitting layer, and a negative electrode in this order, the light-emitting layer containing delayed fluorescent compound M2 and compound M3 having...
|
|
WO/2021/166553A1 |
An organic electroluminescent element which includes an anode, a cathode, and a luminescent layer disposed between the anode and the cathode, wherein the luminescent layer comprises delayed fluorescent compound M2 having at least one deu...
|
|
WO/2021/163254A1 |
The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds...
|
|
WO/2021/160134A1 |
Provided are a compound as represented by formula I, a preparation method therefor, and a hydrochloride crystal form A thereof. The compound as represented by formula I and the hydrochloride crystal form A thereof have excellent inhibito...
|
|
WO/2021/162057A1 |
This organic electroluminescent element (1) includes at least two light emitting units (11, 12) arranged between an anode (3) and a cathode (4), and a first cathode-side organic layer (21), wherein: the first cathode-side organic layer (...
|
|
WO/2021/154997A1 |
The disclosure provides at least one entity chosen from compounds of Formula (I) pharmaceutically acceptable salts thereof, solvates of any of the foregoing, and deuterated derivatives of any of the foregoing, compositions comprising the...
|
|
WO/2021/149998A1 |
The present invention provides a novel compound, an organic electric element using same, and an electronic device having same, the novel compound capable of improving the light-emitting efficiency, stability and lifespan of the element.
|
|
WO/2021/143822A1 |
The present invention relates to a bicyclic imide derivative, a preparation method thereof, and an application thereof in medicine. Specifically, the present invention relates to a novel ligand compound of bicyclic imide represented by g...
|
|
WO/2021/145651A1 |
The present invention provides a novel compound capable of improving light-emitting efficiency, stability and lifespan of an element, an organic electrical element using the novel compound, and an electronic device having the organic ele...
|
|
WO/2021/141356A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode; and ...
|
|
WO/2021/136238A1 |
Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen o...
|
|
WO/2021/135456A1 |
An organic compound represented by chemical formula 1 and chemical formula 2, an electronic component and an electronic device. Any adjacent two * among the two * in chemical formula 2 and the four * in chemical formula 1 may bond so as ...
|
|
WO/2021/122538A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/120838A1 |
Disclosed is an organic compound, an electronic device containing the organic compound, and an electronic apparatus having the electronic device. A main structure of the organic compound is a fused heterocyclic aromatic group containing ...
|
|
WO/2021/118234A1 |
The present invention relates to a novel furan-based compound, a novel epoxy compound, and a method for preparing same. Specifically, the present invention relates to a bio-raw-material-based multi-furan monomer, a multi-furan monomer-ba...
|
|
WO/2021/116398A1 |
The present invention is directed to use of kifunensine for increasing sialylation of a glycosylated polypeptide, wherein a cell that produces the glycosylated polypeptide is contacted with kifunensine. Also provided are related methods ...
|
|
WO/2021/116260A1 |
The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are quinazoline derivatives, methods of preparing such compounds...
|
|
WO/2021/113506A1 |
Provided are certain ATM kinase inhibitors of Formula (I). Also provided herein are compositions of such compounds, and methods of their use.
|
|
WO/2021/111351A1 |
The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belo...
|
|
WO/2021/103058A1 |
Disclosed is a hole transport material, a preparation method thereof, and an electroluminescent device. By means of a sophisticated molecular design and based on a xanthene structure as well as different electron-donating groups, a serie...
|
|
WO/2021/107030A1 |
This compound is represented by formula (12X). In formula (12X), Py1 and Py2 each independently represent a substituted or unsubstituted 1-pyrenyl group, and L1 and L2 each independently represent a substituted or unsubstituted phenylene...
|
|
WO/2021/108191A1 |
The disclosure provides recording materials including aromatic substituted alkane-core derivatized monomers and polymers for use in volume Bragg gratings, including, but not limited to, volume Bragg gratings for holography applications. ...
|
|
WO/2021/103728A1 |
An organic compound and an organic electroluminescent device using the compound used for the field of organic electroluminescence. The organic compound is as shown in structural formula I, wherein Ar1 to Ar 4 are independently selected f...
|
|
WO/2021/101919A1 |
Disclosed are compounds of Formula (I) or a salt thereof, wherein Z is CR6R6 or C=O; Ring A is, and R1, R2, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharma...
|
|
WO/2021/097875A1 |
Disclosed is a bio-based intrinsic flame-retardant epoxy resin precursor employing a natural flavonoid compound and an application thereof in the preparation of an epoxy resin. The precursor has a structure as shown in formula (I) and fo...
|
|
WO/2021/101112A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2021/093820A1 |
An amide derivative and an application thereof in medicine, specifically relating to the amide derivative represented by general formula (I) or a stereoisomer, solvate, a metabolic product, a deuterated product, a prodrug, a pharmaceutic...
|
|
WO/2021/088999A1 |
A compound having therapeutic efficacy for liver disease. The compound may be the compound as represented by formula (I), an optical isomer of same, or a pharmaceutically acceptable salt thereof. The compound is applicable in the treatme...
|
|
WO/2021/086977A1 |
Described herein are 1,2-dioxetanes that are useful as chemiluminescent probes, diagnostic agents, and imaging agents. Also described herein are compositions containing such compounds and methods of using the same.
|
|
WO/2021/083060A1 |
The present invention relates to a five-membered heterocyclic oxocarboxylic acid compound and the medical use thereof. Specifically, the present invention relates to a compound as represented by formula (I) and a pharmaceutically accepta...
|
|
WO/2021/080950A1 |
A method of identifying a subject having a hematological cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the hematological cancer; obtaining a sample fr...
|
|
WO/2021/080334A1 |
The present invention relates to a compound for an organic electronic element, an organic electronic element using same, and an electronic device comprising the organic electronic element. According to the present invention, an organic e...
|
|
WO/2021/068815A1 |
Disclosed in the present invention are a carboxylic acid ester compound and an application thereof, the structure of the compound being shown in general formula I, and the definition of each substituent in general formula I being provide...
|
|
WO/2021/064189A2 |
The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them hig...
|
|
WO/2021/064142A1 |
The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof : formula (I) and to pharmac...
|
|
WO/2021/063346A1 |
A novel KRAS G12C inhibitor. A compound represented by formula (I) and an isomer or pharmaceutically acceptable salt thereof have the following structure. The compound represented by formula (I) and a composition thereof may effectively ...
|
|
WO/2021/066319A2 |
Provided is a tertiary amine derivative which effectively absorbs a high-energy external light source in the UV region to minimize damage to organic materials in an organic electroluminescent element, thereby contributing to a substantia...
|
|
WO/2021/060723A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic layer placed between the first and second electrodes; and an ele...
|
|
WO/2021/048229A1 |
The present invention relates to copolymers comprising moieties able to undergo a crosslinking reaction under certain stimuli, thereby forming polymer adducts having improved or additional properties, such as resistance to solvents, incr...
|
|
WO/2021/046447A1 |
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed com...
|
|
WO/2021/043755A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/037077A1 |
Patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
|
|
WO/2021/032687A1 |
A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, and analogues thereof, substituted in the 6-position by an arylcarbonylaminophenyl or heteroarylcarbonylaminophenyl moiety, being potent inhibitors of the growth and propa...
|
|
WO/2021/033731A1 |
Provided is a compound which is represented by formula (1). In the formula, R1-R14, L1-L3, p, q, r, n, and X1 are as defined in the specification.
|
|
WO/2021/034089A1 |
The present invention relates to a compound for an organic electronic element, an organic electronic element using same, and an electronic device including the organic electronic element. According to the present invention, an organic el...
|
